Ozan Unlu1, Emily B Levitan2, Evgeniya Reshetnyak3, Jerard Kneifati-Hayek4, Ivan Diaz5, Alexi Archambault3, Ligong Chen2, Joseph T Hanlon6, Mathew S Maurer7, Monika M Safford3, Mark S Lachs8, Parag Goyal3,9. 1. Department of Medicine (O.U.), Weill Cornell Medicine, New York, NY. 2. Department of Epidemiology, University of Alabama at Birmingham (E.B.L., L.C.). 3. Division of General Internal Medicine/Department of Medicine (E.R., A.A., M.M.S., P.G.), Weill Cornell Medicine, New York, NY. 4. Division of General Internal Medicine (J.K.-H.), Columbia University Medical Center, New York, NY. 5. Department of Healthcare Policy and Research (I.D.), Weill Cornell Medicine, New York, NY. 6. Department of Medicine, University of Pittsburgh, PA (J.T.H.). 7. Division of Cardiology (M.S.M.), Columbia University Medical Center, New York, NY. 8. Division of Geriatrics/Department of Medicine (M.L.), Weill Cornell Medicine, New York, NY. 9. Division of Cardiology/Department of Medicine (P.G.), Weill Cornell Medicine, New York, NY.
Abstract
BACKGROUND: Despite potential harm that can result from polypharmacy, real-world data on polypharmacy in the setting of heart failure (HF) are limited. We sought to address this knowledge gap by studying older adults hospitalized for HF derived from the REGARDS study (Reasons for Geographic and Racial Differences in Stroke). METHODS: We examined 558 older adults aged ≥65 years with adjudicated HF hospitalizations from 380 hospitals across the United States. We collected and examined data from the REGARDS baseline assessment, medical charts from HF-adjudicated hospitalizations, the American Hospital Association annual survey database, and Medicare's Hospital Compare website. We counted the number of medications taken at hospital admission and discharge; and classified each medication as HF-related, non-HF cardiovascular-related, or noncardiovascular-related. RESULTS: The vast majority of participants (84% at admission and 95% at discharge) took ≥5 medications; and 42% at admission and 55% at discharge took ≥10 medications. The prevalence of taking ≥10 medications (polypharmacy) increased over the study period. As the number of total medications increased, the number of noncardiovascular medications increased more rapidly than the number of HF-related or non-HF cardiovascular medications. CONCLUSIONS: Defining polypharmacy as taking ≥10 medications might be more ideal in the HF population as most patients already take ≥5 medications. Polypharmacy is common both at admission and hospital discharge, and its prevalence is rising over time. The majority of medications taken by older adults with HF are noncardiovascular medications. There is a need to develop strategies that can mitigate the negative effects of polypharmacy among older adults with HF.
BACKGROUND: Despite potential harm that can result from polypharmacy, real-world data on polypharmacy in the setting of heart failure (HF) are limited. We sought to address this knowledge gap by studying older adults hospitalized for HF derived from the REGARDS study (Reasons for Geographic and Racial Differences in Stroke). METHODS: We examined 558 older adults aged ≥65 years with adjudicated HF hospitalizations from 380 hospitals across the United States. We collected and examined data from the REGARDS baseline assessment, medical charts from HF-adjudicated hospitalizations, the American Hospital Association annual survey database, and Medicare's Hospital Compare website. We counted the number of medications taken at hospital admission and discharge; and classified each medication as HF-related, non-HF cardiovascular-related, or noncardiovascular-related. RESULTS: The vast majority of participants (84% at admission and 95% at discharge) took ≥5 medications; and 42% at admission and 55% at discharge took ≥10 medications. The prevalence of taking ≥10 medications (polypharmacy) increased over the study period. As the number of total medications increased, the number of noncardiovascular medications increased more rapidly than the number of HF-related or non-HF cardiovascular medications. CONCLUSIONS: Defining polypharmacy as taking ≥10 medications might be more ideal in the HF population as most patients already take ≥5 medications. Polypharmacy is common both at admission and hospital discharge, and its prevalence is rising over time. The majority of medications taken by older adults with HF are noncardiovascular medications. There is a need to develop strategies that can mitigate the negative effects of polypharmacy among older adults with HF.
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff Journal: Circulation Date: 2013-06-05 Impact factor: 29.690
Authors: John J V McMurray; Scott D Solomon; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Inder S Anand; Jan Bělohlávek; Michael Böhm; Chern-En Chiang; Vijay K Chopra; Rudolf A de Boer; Akshay S Desai; Mirta Diez; Jaroslaw Drozdz; Andrej Dukát; Junbo Ge; Jonathan G Howlett; Tzvetana Katova; Masafumi Kitakaze; Charlotta E A Ljungman; Béla Merkely; Jose C Nicolau; Eileen O'Meara; Mark C Petrie; Pham N Vinh; Morten Schou; Sergey Tereshchenko; Subodh Verma; Claes Held; David L DeMets; Kieran F Docherty; Pardeep S Jhund; Olof Bengtsson; Mikaela Sjöstrand; Anna-Maria Langkilde Journal: N Engl J Med Date: 2019-09-19 Impact factor: 91.245
Authors: Parag Goyal; Jerard Kneifati-Hayek; Alexi Archambault; Krisha Mehta; Emily B Levitan; Ligong Chen; Ivan Diaz; James Hollenberg; Joseph T Hanlon; Mark S Lachs; Mathew S Maurer; Monika M Safford Journal: JACC Heart Fail Date: 2020-03 Impact factor: 12.035
Authors: Eiran Z Gorodeski; Parag Goyal; Scott L Hummel; Ashok Krishnaswami; Sarah J Goodlin; Linda L Hart; Daniel E Forman; Nanette K Wenger; James N Kirkpatrick; Karen P Alexander Journal: J Am Coll Cardiol Date: 2018-05-01 Impact factor: 24.094
Authors: Parag Goyal; Eiran Z Gorodeski; Kelsey M Flint; Deena S Goldwater; John A Dodson; Jonathan Afilalo; Mathew S Maurer; Michael W Rich; Karen P Alexander; Scott L Hummel Journal: J Am Geriatr Soc Date: 2019-10-18 Impact factor: 5.562
Authors: Masatoshi Minamisawa; Brian Claggett; Kota Suzuki; Sheila M Hegde; Amil M Shah; Akshay S Desai; Eldrin F Lewis; Sanjiv J Shah; Nancy K Sweitzer; James C Fang; Inder S Anand; Eileen O'Meara; Jean-Lucien Rouleau; Bertram Pitt; Marc A Pfeffer; Scott D Solomon; Orly Vardeny Journal: Circ Heart Fail Date: 2021-10-22 Impact factor: 8.790
Authors: Quin E Denfeld; Beth A Habecker; S Albert Camacho; Mary Roberts Davis; Nandita Gupta; Shirin O Hiatt; Mary E Medysky; Jonathan Q Purnell; Kerri Winters-Stone; Christopher S Lee Journal: Circ Heart Fail Date: 2021-08-25 Impact factor: 10.447